Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3Terminated 1

Sponsor Class

NETWORK 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Dermatologic 1

Conditions

Neuroblastoma 2Melanoma 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Has results × lorukafusp alfa × Clear all
NCT00590824 2019-11-21

Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma

University of Wisconsin, Madison

Phase 2 Completed
23 enrolled 22 charts
Dermatologic

Melanoma

NCT01334515 2019-10-21

Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma

Children's Oncology Group

Phase 2 Completed
52 enrolled 11 charts
CNS

Neuroblastoma

NCT00082758 2015-02-12

hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Children's Oncology Group

Phase 2 Completed
39 enrolled 8 charts
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡